Are We Ready to Treat Diffuse Large B‐cell and High‐Grade Lymphoma According to Major Genetic Subtypes?
Annalisa Chiappella(Palmetto Hematology Oncology), Paolo Corradini(Gruppo di Ricerca Geriatrica), Umberto Vitolo(Candiolo Cancer Institute), Philippe Armand(Harvard University), Anna Guidetti(Fondazione IRCCS Istituto Nazionale dei Tumori), Jennifer L. Crombie(Dana-Farber Cancer Institute)
Cited by 14
Related Papers
PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma
|New England Journal of Medicine|2014|3.5k
Ipilimumab for Patients with Relapse after Allogeneic Transplantation
|New England Journal of Medicine|2016|595
Management of Immunotherapy-Related Toxicities, Version 1.2019, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2019|560
NCCN Guidelines Insights: Management of Immunotherapy-Related Toxicities, Version 1.2020
|Journal of the National Comprehensive Cancer Network|2020|484
Clonal Hematopoiesis Associated With Adverse Outcomes After Autologous Stem-Cell Transplantation for Lymphoma
|Journal of Clinical Oncology|2017|468